×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ADAG – adagene inc. - ads, each representing 1.25 ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ADAG
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/26
06:43 am
adag
Adagene (NASDAQ:ADAG) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Medium
Report
Adagene (NASDAQ:ADAG) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
11/24
07:19 am
adag
Adagene (NASDAQ:ADAG) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Medium
Report
Adagene (NASDAQ:ADAG) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
11/15
10:32 am
adag
Adagene (NASDAQ:ADAG) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Low
Report
Adagene (NASDAQ:ADAG) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
11/13
07:11 am
adag
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology [Yahoo! Finance]
Medium
Report
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology [Yahoo! Finance]
11/13
07:00 am
adag
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Low
Report
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
10/31
07:00 am
adag
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
Low
Report
Adagene Announces First Patient Dosed in Randomized Dose Optimization Cohort of the Phase 2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Microsatellite Stable Colorectal Cancer
10/3
02:37 pm
adag
Adagene (NASDAQ:ADAG) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Neutral
Report
Adagene (NASDAQ:ADAG) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
9/16
08:00 am
adag
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Low
Report
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
05:43 pm
adag
Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.
Low
Report
Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.
11/14
04:35 pm
adag
Form SCHEDULE 13G/A Adagene Inc. Filed by: Panacea Innovation Ltd
Low
Report
Form SCHEDULE 13G/A Adagene Inc. Filed by: Panacea Innovation Ltd
11/13
07:01 am
adag
Form 6-K Adagene Inc. For: Nov 13
Low
Report
Form 6-K Adagene Inc. For: Nov 13
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: